Outsourcing-Pharma presents its weekly round-up of the latest new faces and movers in the pharmaceutical industry, including news from Quintiles, Clinipace and Elsevier.
Quintiles has drafted in Tom Pike as CEO, replacing Dennis Gillings.
The former Accenture’s chief risk officer’s appointment is part of the firm’s “long-term succession planning” which will see Gillings taking a step down to become executive chairman of the board.
Speaking to Outsourcing-Pharma earlier this week , spokesman Phil Bridges said: “He understands the challenges of working in this environment” and has “dealt with complex clients and the issues of growing a complex global organization.”
Pike added: “Healthcare is the most important industry of the next quarter century, and I'm excited because Quintiles is right at the centre of improving the health of millions of people around the world.”
Ran Frenkel has been named VP of Investigator Initiated Sponsored Research Association (IISRA).
Frenkel – currently VP of international business development for dCRO (digital clinical research organisation) Clinipace – will also join the 2012-13 board of directors for the association, which supports independent scientific research.
“As a digital clinical research organization, it is one of our primary missions to do our part in promoting excellence in the development of investigator initiated trials and sponsored research programs,” said Frenkel. “That being said, it’s an honour to serve on such a distinguished panel of dedicated professionals.”
Elsevier has named Jim Donohue as managing director of its clinical reference group Elsevier Health Sciences.
Donohue takes the role after working as senior VP and general manager of Elsevier’s MD Consult. He first joined the firm in 2006.
In his new position, he will take charge of the launch of ClinicalKey, the world’s first “clinical insight engine”. A spokesperson for the firm said the program will provide “relevant, fast, trusted and comprehensive clinical answers for clinicians.”
Michael Hansen, CEO of Elsevier Health Sciences, added: “Healthcare is increasingly content and data-driven, and we are continuously looking for new and better ways to put our world-leading medical reference content into the hands of clinicians around the globe.”
Healthcare ad agency AbelsonTaylor has promoted Beth Fullen and Paul Pela to the positions of senior artist.
Fullen, formerly a graphic designer for Medicis Pharmaceutical Corp, will work on journal ads, panels for show booths and other materials, working largely in the field of cholesterol-related brands.
Pela, who was previously a graphic designer for EURO RSCG,will be in charge of products ranging from for the treatment of anemia and GERD to nutritional supplements.
Theorem Clinical Research has promoted Patricia Bland as executive director of corporate development.
She joins the firm from pharma consultancy D&D Strategic Solutions, where she was managing principal for a consulting services.
Bland will now take on responsibility for Theorum’s company proposals, customer contracts and marketing, operational vendor management, investigator feasibility and relations, and business intelligence.
“Patricia encompasses the expertise we were looking for in an executive director of corporate development,” said CEO John Potthoff.
Regulatory advisors Becker & Associates Consulting has added six new members and affiliates.
New to the consulting team – six Sigma Black Beltholder Mary Getz will be director of Quality Systems, the principal consultantrole goes to Larry Schum, EU regulatory specialist Carrie Neuberger is new director of European strategies, Merry Lee Bain has been named regulatory Expert.
The expert advisory committee will be made up of former director of the office of compliance for CDRH Tim Ulatowski – who becomes compliance and regulatory expert at Becker – and his former assistant Wally Pellerite, who is now compliance expert.
“These individuals will bring a diverse range of former FDA and industry expertise to domestic and international healthcare companies in need of regulatory and quality systems support,” said a spokesperson.